Back to first-pass browser

First-pass extracted concept

CRISPR/Cas-guided single-guide RNAs

Candidate: toolkit item1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

CRISPR/Cas-guided single-guide RNAs are presented as part of the RNA therapeutic landscape covered by the review. The abstract associates RNA-based strategies with editing applications.

Source 1DOIPubMed

Resources required

The abstract indicates that delivery technologies are important for RNA therapeutics broadly. It does not specify Cas protein format or delivery details in the abstract.

Source 1DOIPubMed

What problem it solves

This modality supports therapeutic editing-oriented intervention within RNA-targeted medicine.

Source 1DOIPubMed

What it does not solve

The abstract notes general translational barriers for RNA therapeutics, including stability, delivery efficiency, and immune activation.

Source 1DOIPubMed

Alternatives

The review discusses this modality alongside ASOs, siRNA, miRNA modulators, mRNA therapeutics, aptamers, and shRNA.

Source 1DOIPubMed

Evidence Snippets

Advances in high-throughput sequencing, structural biology, and delivery technologies have accelerated the development of diverse RNA therapeutics, including CRISPR/Cas-guided single-guide RNAs.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1application scopesupports2026Source 1DOIPubMed

RNA-based strategies are applied to gene silencing, editing, protein replacement, immune activation, and targeted drug delivery.

Claim 2field shiftsupports2026Source 1DOIPubMed

RNA-targeted therapy is shifting molecular medicine from a protein-centric view toward an RNA-regulatory network paradigm.

Claim 3modality coveragesupports2026Source 1DOIPubMed

Diverse RNA therapeutics include ASOs, siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.

Claim 4translational barriersupports2026Source 1DOIPubMed

Common challenges for RNA therapeutics include in vivo stability, delivery efficiency, and immune activation.